Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 2
2007 3
2008 3
2009 1
2010 2
2011 4
2012 8
2013 7
2014 3
2015 4
2016 1
2018 1
2020 3
2021 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Acute service and disability service providers experiences of joint working to improve health care experiences of people with an intellectual disability compared to non-joint working: A mixed-method systematic review.
Kelleher E, Martin AM, Caples M, Wills T. Kelleher E, et al. Among authors: martin am. J Intellect Disabil. 2023 Oct 21:17446295231209345. doi: 10.1177/17446295231209345. Online ahead of print. J Intellect Disabil. 2023. PMID: 37864518 Free article. Review.
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Diwanji R, O'Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA, Piquet M, Pelletier MR, Savchenko A, Charette L, Rodrik-Outmezguine V, Baum J, Millholland JM, Wong CC, Martin AM, Dranoff G, Pruteanu-Malinici I, Cremasco V, Sabatos-Peyton C, Jayaraman P. Diwanji R, et al. Among authors: martin am. Cancer Immunol Res. 2023 Jun 2;11(6):777-791. doi: 10.1158/2326-6066.CIR-22-0290. Cancer Immunol Res. 2023. PMID: 37040466
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: martin am. PLoS One. 2022 Oct 10;17(10):e0276211. doi: 10.1371/journal.pone.0276211. eCollection 2022. PLoS One. 2022. PMID: 36215283 Free PMC article.
Determining the need for a breast cancer awareness educational intervention for women with mild/moderate levels of intellectual disability: A qualitative descriptive study.
Walsh S, Hegarty J, Lehane E, Farrell D, Taggart L, Kelly L, Sahm L, Corrigan M, Caples M, Martin AM, Tabirca S, Corrigan MA, O'Mahony M. Walsh S, et al. Among authors: martin am. Eur J Cancer Care (Engl). 2022 Jul;31(4):e13590. doi: 10.1111/ecc.13590. Epub 2022 Apr 7. Eur J Cancer Care (Engl). 2022. PMID: 35393746 Free PMC article. Review.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: martin am. PLoS One. 2021 Dec 23;16(12):e0261994. doi: 10.1371/journal.pone.0261994. eCollection 2021. PLoS One. 2021. PMID: 34941969 Free PMC article.
Defining breast cancer awareness and identifying barriers to breast cancer awareness for women with an intellectual disability: A review of the literature.
Walsh S, O'Mahony M, Hegarty J, Farrell D, Taggart L, Kelly L, Sahm L, Corrigan M, Caples M, Martin AM, Tabirca S, Corrigan MA, Lehane E. Walsh S, et al. Among authors: martin am. J Intellect Disabil. 2021 Mar 26:1744629521999548. doi: 10.1177/1744629521999548. Online ahead of print. J Intellect Disabil. 2021. PMID: 33769130
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
Wong CC, Baum J, Silvestro A, Beste MT, Bharani-Dharan B, Xu S, Wang YA, Wang X, Prescott MF, Krajkovich L, Dugan M, Ridker PM, Martin AM, Svensson EC. Wong CC, et al. Among authors: martin am. Cancer Res. 2020 Dec 15;80(24):5597-5605. doi: 10.1158/0008-5472.CAN-19-3176. Epub 2020 Oct 6. Cancer Res. 2020. PMID: 33023946 Clinical Trial.
The Effect of Dietary Supplementation on Aggressive Behaviour in Australian Adult Male Prisoners: A Feasibility and Pilot Study for a Randomised, Double Blind Placebo Controlled Trial.
Cortie CH, Byrne MK, Collier C, Parletta N, Crawford D, Winberg PC, Webster D, Chapman K, Thomas G, Dally J, Batterham M, Martin AM, Grant L, Meyer BJ. Cortie CH, et al. Among authors: martin am. Nutrients. 2020 Aug 27;12(9):2617. doi: 10.3390/nu12092617. Nutrients. 2020. PMID: 32867282 Free PMC article. Clinical Trial.
49 results